iTeos

iTeos Therapeutics is developing next generation immunotherapies targeting inflamed and non-inflamed tumors. Lead programs include a best-in-class adenosine A2A receptor antagonist for cancer immunotherapy and a highly differentiated anti-TIGIT mAb.